Background High concentrations of both phosphate and fibroblast growth factor 23 (FGF23)
observed in chronic kidney disease (CKD) are associated with an increased risk of …

Few clinical studies have investigated the value of phosphate (P)-lowering therapies in early
chronic kidney disease (CKD) patients in whom hyperphosphataemia has not yet clearly …

BACKGROUND: Fibroblast growth factor 23 (FGF-23) is a marker of endothelial dysfunction
and atherosclerotic complications in patients with chronic kidney disease (CKD). Because …

Serum phosphate independently predicts cardiovascular mortality in the general population
and CKD, even when levels are in the normal range. Associations between serum …

Abstract Background/Aims: Cardiovascular disease (CVD) is increased in chronic kidney
disease (CKD), and contributed to by the CKD-mineral bone disorder (CKD-MBD). CKD …

Background: Increased levels of phosphate and fibroblast growth factor-23 (FGF23) are
strong predictors of cardiovascular morbidity and mortality in patients with chronic kidney …

Background: Elevated fibroblast growth factor 23 (FGF23) levels are associated with
progression of chronic kidney disease (CKD) and increased mortality. Studies in individuals …

Elevated serum phosphate and fibroblast growth factor 23 (FGF23) levels are associated
with cardiovascular disease (CVD) in patients with chronic renal failure (CRF). The …

Aims Fibroblast growth factor 23 (FGF 23) and K lotho are associated with vascular
calcification and cardiovascular disease in dialysis patients. Sevelamer has been shown to …

Results Of 96 screened patients, 78 (mean±SD age: 63±13 years old; 70% men; mean
eGFR: 27±9 ml/min per 1.73 m 2) met the inclusion criteria. At baseline, mean eGFR was …